← Oncology Approval Tracker

FDA DECISION ·

Xbryk

denosumab-dssb · Samsung Bioepis

Biosimilar approvalBiosimilarCancer-related skeletal complications and giant cell tumor of bone
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Xgeva biosimilar for preventing skeletal complications in multiple myeloma or solid tumor bone metastases, treating giant cell tumor of bone in eligible adults and skeletally mature adolescents, and treating malignancy-related hypercalcemia refractory to bisphosphonates.

LAMPGEN ANALYSIS

Why it matters

This oncology-dose denosumab approval adds a biosimilar option for the labeled Xgeva uses.

What research teams should watch

Keep the generic name and product presentation visible in orders so the Prolia- and Xgeva-referenced products are easy to distinguish.

PRIMARY RECORDS

Sources